Last Updated on July 07, 2006 7:30 pm
|
Chart | TradeSelf Station | History | My Profile | Log Out |
|
|
TODAY STOCK MARKET
--- TODAY STOCK PICKS ---- Our stock picking system has picked TOMO (Tom Online Inc) today. The simulation software will buy this stock on July 10, 2006 at OPEN price. Our Loss Stop is at -28% Do not hold if stock drops more than 28%. Please visit us next trading day after 9 o'clock for the next move.
Please see the below signals for the next trading day
|
TOM Online Inc.
Forgent Networks Inc.
Forgent Networks, Inc. operates as a licensor of intellectual property. It also provides scheduling and asset management software solutions that enable organizations to schedule and manage their office environment. The company’s intellectual property licensing business primarily includes a patent licensing program, which licenses its data compression technology. Forgent Networks’ software products include Meeting Room Manager, which provides a meeting logistics and room scheduling solution; Resource Scheduler, which allows businesses to schedule resources other than meeting rooms, such as shared equipment or other resources through an intuitive and customizable interface; and Visual Asset Manager, which enables companies to track and manage their fixed, mobile, and IT assets across the entire organization from any Web browser. The company also provides professional services for installation of and training on its software. It markets its products primarily small to medium-sized businesses and departments of enterprise organizations in the United States, Europe, and Asia Pacific. Forgent was founded in 1985 and is headquartered in Austin, Texas.
Genaera Corporation, a biopharmaceutical company, engages in the research and development of medicines with focus on antiangiogenesis and respiratory diseases. The company’s primary product EVIZON is under Phase II and Phase III clinical trials to treat ophthalmic indications, specifically the ‘wet’ form of age related macular degeneration. It is also developing Squalamine Lactate, a Phase II clinical trail product, for the treatment of cancerous solid tumors; LOMUCIN, a Phase II clinical trail product, to treat the overproduction of mucus secretions involved in chronic respiratory disease; and interleukin-9 antibody, a respiratory treatment based on the discovery of a genetic cause of asthma. In addition, the company has various discovery research programs focused on the treatment of obesity, infectious diseases, and inflammatory disorders. The company has a collaborative agreement with MedImmune, Inc. to develop and commercialize interleukin-9. Genaera Corporation was incorporated in 1987 and is headquartered in Plymouth Meeting, Pennsylvania. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SIMULATION
PERFORMANCE RESULTS HAVE INHERENT LIMITATIONS, THE PERFORMANCE
TABLES AND RESULTS ARE BASED ON BACKTESTING OF CERTAIN TRADING
STRATEGIES. DO NOT REPRESENT TRADING IN ACTUAL ACCOUNTS
You may have more losses or profits in your account comparing to other
member accounts due to many factors, including but not limited to: you and
other people may trade stock picks in different orders, orders not get
filled or partially get filled, selective trading some specific stock picks
instead of all stock picks, paying different commission fees required by
different brokerages, stock positions entered and exited at different price
other than our suggested price due to market orders, order execution
delayed, various human decisions or technical failures.
You
may lose all of your money when investing and trading in the stock markets! The data contained in the reports within this site is provided for
informational purposes only. It should not be viewed as a solicitation for
the referenced system or vendor. While the information and statistics given
are believed to be complete and accurate, we cannot guarantee their
completeness or accuracy. As past performance does not guarantee future
results, these results may have no bearing on, and may not be indicative of,
any individual returns realized through participation in this or any other
investment. No part of this document should be considered apart from the
Disclosure Statements contained herein.
My Profile | Logout l Home l Subscribe l Site Requirements l Privacy l Security l